Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review
- PMID: 35535227
- PMCID: PMC9078812
- DOI: 10.1155/2022/1721526
Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review
Retraction in
-
Retracted: Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review.Comput Math Methods Med. 2023 Dec 6;2023:9781303. doi: 10.1155/2023/9781303. eCollection 2023. Comput Math Methods Med. 2023. PMID: 38094448 Free PMC article.
Abstract
Whether TERT promoter mutation is related to more aggressive clinicopathologic features and worse outcomes in papillary thyroid carcinoma patients (PTCs) is still variable and controversial. Our intention was to investigate the risk or prognostic factors that may additionally predict the TERT promoter mutation doable of these lesions and new prevention techniques in PTCs. A total of 2,539 PTC patients with 11.50% TERT mutation have been analyzed using Revman 5.3 software in this study. The PubMed and Embase databases were systematically searched for works published until November 9, 2021. The following variables had been associated with an extended chance of TERT promoter mutation in PTC patients: age < 45 years (MD = 10.93, 95%CI = 7.25-14.61); gender = male (pooled OR = 1.63, 95%CI = 1.17-2.28); tumor size > 1 cm (MD = 0.56, 95%CI = 0.34-0.77); lymph node metastasis (pooled OR = 1.29, 95%CI = 0.93-1.79); vascular invasion (pooled OR = 1.78, 95%CI = 0.83-3.84); extrathyroidal extension (pooled OR = 2.00, 95%CI = 1.32-3.02); distant metastasis (pooled OR = 1.46, 95%CI = 1.04-2.04); advanced TNM stage (pooled OR = 3.19, 95%CI = 2.28-4.45). In addition, multifocality (pooled OR = 0.67, 95%CI = 0.14-3.24) had no affiliation with TERT promoter mutation in PTC patients. Our finding showed that age < 45 years, male, tumor size > 1 cm, lymph node metastasis, vascular invasion, and superior/advanced TNM stage were dangerous elements for TERT promoter mutation of worse effect in PTCs while that multifocality was once negatively correlated. TERT promoter mutation is drastically associated with recurrence and PTC-related mortality.
Copyright © 2022 Jingxin Mao et al.
Conflict of interest statement
All authors declare that there has not any commercial or associative interest that represents a conflict of interest in connection with the work submitted.
Figures











Similar articles
-
Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.Diagn Pathol. 2019 Jul 12;14(1):74. doi: 10.1186/s13000-019-0849-6. Diagn Pathol. 2019. PMID: 31300059 Free PMC article.
-
Effects of Coexistent BRAFV600E and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis.Thyroid. 2017 May;27(5):651-660. doi: 10.1089/thy.2016.0350. Epub 2017 Mar 7. Thyroid. 2017. PMID: 28181854
-
Progression of Papillary Thyroid Carcinoma to Anaplastic Carcinoma in Metastatic Lymph Nodes: Solid/Insular Growth and Hobnail Cell Change in Lymph Nodes Are Predictors of Subsequent Anaplastic Transformation.Endocr Pathol. 2021 Sep;32(3):347-356. doi: 10.1007/s12022-021-09674-1. Epub 2021 Mar 24. Endocr Pathol. 2021. PMID: 33761111 Free PMC article.
-
Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.Front Endocrinol (Lausanne). 2020 May 15;11:265. doi: 10.3389/fendo.2020.00265. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32477264 Free PMC article.
-
Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.Endocrine. 2020 Jan;67(1):44-57. doi: 10.1007/s12020-019-02117-2. Epub 2019 Oct 26. Endocrine. 2020. PMID: 31655978 Free PMC article.
Cited by
-
Identification of useful biomolecular markers in kidney renal clear cell carcinoma: an in silico and in vitro analysis-based study.Am J Transl Res. 2023 Sep 15;15(9):5574-5593. eCollection 2023. Am J Transl Res. 2023. PMID: 37854221 Free PMC article.
-
Retracted: Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review.Comput Math Methods Med. 2023 Dec 6;2023:9781303. doi: 10.1155/2023/9781303. eCollection 2023. Comput Math Methods Med. 2023. PMID: 38094448 Free PMC article.
-
Transcriptomics data mining to uncover signature genes in head and neck squamous cell carcinoma: a bioinformatics analysis and RNA-sequencing based validation.Am J Cancer Res. 2023 Nov 15;13(11):5513-5530. eCollection 2023. Am J Cancer Res. 2023. PMID: 38058845 Free PMC article.
-
A pan-cancer analysis of pituitary tumor-transforming 3, pseudogene.Am J Transl Res. 2023 Aug 15;15(8):5408-5424. eCollection 2023. Am J Transl Res. 2023. PMID: 37692950 Free PMC article.
-
TERT promoter mutations and gene amplification in endometrial cancer.Gynecol Oncol. 2023 Dec;179:16-23. doi: 10.1016/j.ygyno.2023.10.007. Epub 2023 Oct 25. Gynecol Oncol. 2023. PMID: 37890416 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources